Allex (actinidia arguta extract) / Helixmith, SBI Biotech - LARVOL DELTA

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injections of PG-102 (MG12) in Healthy Adult and Obesity Participants. (clinicaltrials.gov) - P1 | N=102 | Completed | Sponsor: ProGen. Co., Ltd. | Recruiting ➔ Completed | Trial completion date: Oct 2026 ➔ Feb 2025 | Trial primary completion date: Feb 2026 ➔ Feb 2025

Trial completion • Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

An Early Phase Study of RT-114 (clinicaltrials.gov) - P1 | N=60 | Not yet recruiting | Sponsor: RANI Therapeutics

New P1 trial • Genetic Disorders • Obesity

Phase II Study of PG-102(MG12) Compared with Placebo in Obesity and Type 2 Diabetes (clinicaltrials.gov) - P2 | N=144 | Recruiting | Sponsor: ProGen. Co., Ltd. | Enrolling by invitation ➔ Recruiting

Enrollment status • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Phase II Study of PG-102(MG12) Compared with Placebo in Obesity and Type 2 Diabetes (clinicaltrials.gov) - P2 | N=144 | Enrolling by invitation | Sponsor: ProGen. Co., Ltd. | Not yet recruiting ➔ Enrolling by invitation

Enrollment open • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injections of PG-102 (MG12) in Healthy Adult and Obesity Participants. (clinicaltrials.gov) - P1 | N=118 | Recruiting | Sponsor: ProGen. Co., Ltd. | N=90 ➔ 118 | Initiation date: Oct 2023 ➔ Mar 2024

Enrollment change • Trial initiation date • Genetic Disorders • Obesity

Phase II Study of PG-102(MG12) Compared With Placebo in Obesity and Type 2 Diabetes (clinicaltrials.gov) - P2 | N=144 | Not yet recruiting | Sponsor: ProGen. Co., Ltd.

New P2 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Study to Assess Safety, Pharmacokinetics and Pharmacodynamics of PG-102(MG12) in Healthy Volunteers (clinicaltrials.gov) - P1 | N=90 | Recruiting | Sponsor: ProGen. Co., Ltd. | Trial completion date: Jun 2024 ➔ Oct 2026 | Trial primary completion date: Jun 2024 ➔ Feb 2026

Trial completion date • Trial primary completion date • Obesity

A Study to Assess Safety, Pharmacokinetics and Pharmacodynamics of PG-102(MG12) in Healthy Volunteers (clinicaltrials.gov) - P1 | N=90 | Recruiting | Sponsor: ProGen. Co., Ltd.

New P1 trial • Obesity

A Water-Soluble Extract from Actinidia arguta (PG102) Can Inhibit Kidney Fibrosis (KIDNEY WEEK 2019) - "In vitro experiment, human kidney proximal tubular cells treated with TGF-β and PG102 showed significantly decreased protein expression of α-smooth muscle actin (47.8% of control), and phospho-p38 (51.5% of control). Conclusion PG102 attenuates kidney fibrosis in the unilateral ureteral obstruction mice model and TGF-β-treated human kidney proximal tubular cells, p38 MAPK pathway is inhibited after treatment of PG102."

SNUG: Safety and Efficacy of PG102P for Uremic Pruritus in HD Patients (clinicaltrials.gov) - P=N/A; N=80; Completed; Sponsor: Seoul National University Boramae Hospital; Recruiting ➔ Completed; Trial primary completion date: Oct 2018 ➔ Jan 2019

Clinical • Trial completion • Trial primary completion date

A Water-Soluble Extract from Actinidia arguta (PG102) can Inhibit Kidney Fibrosis (KSN 2019) - "PG102 attenuates kidney fibrosis in the unilateral ureteral obstruction mice model and TGF-β-treated human kidney proximal tubular cells, p38 MAPK pathway is inhibited after treatment of PG102."